Literature DB >> 23282703

[Hodgkin lymphoma with hepatic involvement treated with dexametasone, gemcitabine and cisplatin as a bridge to standard therapy: report of one case].

Matías Orellana1, Valeria Buttinghausen, Augusto Aspillaga M, Mauricio Chandía C.   

Abstract

The initial presentation of Hodgkin lymphoma with liver involvement is rare. In these patients, the standard first-line therapy with ABVD (Adriamycin, Bleomycine, Vinblastine, Dacarbazine) imply an additional risk for liver toxicity. We report a 64-year-old woman who presented with jaundice, choluria, malaise and weight loss. In the initial evaluation she had jaundice and palpable groin lymph nodes. An obstructive biliary disease was ruled out with magnetic resonance imaging studies. A lymph node biopsy showed a Hodgkins lymphoma, Mixed-cellularity subtype. Considering the liver dysfunction, an alternative scheme of chemotherapy with dexamethasone, gemcitabine and cisplatin (GDP) was administered. After 4 cycles, a significant improvement in liver hepatic function tests was reached and a conventional chemotherapy (ABVD) was begun. While the literature provides some low toxicity protocols for patients with liver involvement, favorable results of our clinical case report allows us to postulate GDP as an alternative for salvage therapy in these patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23282703     DOI: 10.4067/S0034-98872012000700011

Source DB:  PubMed          Journal:  Rev Med Chil        ISSN: 0034-9887            Impact factor:   0.553


  2 in total

1.  Unusual cause of cholestatic jaundice in a patient with AIDS.

Authors:  Su Bin Kim; Makardhwaj Sarvadaman Shrivastava; Jesus M Anampa; Marianna Strakhan
Journal:  BMJ Case Rep       Date:  2013-08-23

2.  CEPP regimen (cyclophosphamide, etoposide, procarbazine and prednisone) as initial treatment for Hodgkin lymphoma patients presenting with severe abnormal liver function.

Authors:  Keyur Thakar; Aileen Novero; Arundhati Das; Adriana Lisinschi; Bella Mehta; Tauseef Ahmed; Delong Liu
Journal:  Biomark Res       Date:  2014-06-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.